Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerating wastewater-based SARS-CoV-2 surveillance using a mobile laboratory in mixed infrastructure regions.

The Science of the total environment·2026
Same author

Selection of Mutations in HIV-1 Nucleocapsid and Integrase in Individuals Living with HIV Experiencing Virologic Failure After Initiating or Switching to Tenofovir-Lamivudine-Dolutegravir.

medRxiv : the preprint server for health sciences·2026
Same author

CXCL13-CXCR5 signaling in CD8<sup>+</sup> T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same author

Diverse Bacterial Properties Influence Dispersal Along Fungal Networks.

Journal of fungi (Basel, Switzerland)·2026
Same author

CXCL13-CXCR5 Signaling in CD8<sup>+</sup> T Cell Recruitment and Lymphoid Immune Organization in Clear Cell Renal Cell Carcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026

Related Experiment Video

Updated: Mar 29, 2026

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

2.2K

Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost.

Scott M Berry1, Hannah M Pezzi1, Eram D Williams2

  • 1Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, Wisconsin, United States of America.

Plos One
|December 3, 2015
PubMed
Summary

A new, low-cost viral load (VL) assay for HIV management in developing countries demonstrates performance equivalent to existing methods. This affordable assay, costing approximately $5 USD, aims to improve access to critical HIV monitoring for patients.

More Related Videos

Unbiased Deep Sequencing of RNA Viruses from Clinical Samples
09:36

Unbiased Deep Sequencing of RNA Viruses from Clinical Samples

Published on: July 2, 2016

17.8K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.3K

Related Experiment Videos

Last Updated: Mar 29, 2026

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

2.2K
Unbiased Deep Sequencing of RNA Viruses from Clinical Samples
09:36

Unbiased Deep Sequencing of RNA Viruses from Clinical Samples

Published on: July 2, 2016

17.8K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.3K

Area of Science:

  • Virology
  • Public Health
  • Biotechnology

Background:

  • Viral load (VL) measurements are essential for effective HIV management, particularly in resource-limited settings.
  • Current VL assays are often too expensive and complex for widespread implementation in developing countries.
  • There is a critical need for cost-effective VL assays that maintain high performance standards.

Purpose of the Study:

  • To develop and validate a novel, low-cost viral load assay for HIV monitoring.
  • To compare the performance of the new assay against a standard VL assay using patient samples.
  • To assess the cost-effectiveness of the new assay for potential use in developing countries.

Main Methods:

  • A new assay combining low-cost reagents with Exclusion-Based Sample Preparation (ESP) for RNA isolation was developed.
  • Seventy-one patient plasma samples with a wide range of viral loads were tested.
  • Performance was evaluated by comparing results with the Abbott RealTime HIV-1 assay, focusing on limit of detection (LOD), accuracy, and dynamic range.

Main Results:

  • The new assay demonstrated a limit of detection (LOD) of approximately 50 copies/mL, comparable to the existing assay.
  • High accuracy was achieved, with an average difference of 0.08 log and an R-squared value of 0.97 when compared to the reference method.
  • The estimated cost of reagents and consumables for the new assay is approximately $5 USD per test.

Conclusions:

  • The developed low-cost VL assay offers performance comparable to established methods.
  • The ESP method simplifies RNA isolation, contributing to reduced assay costs.
  • This assay has the potential to significantly improve access to essential HIV viral load testing in developing countries.